Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ambroxol hydrochloride is a mucolytic agent used to treat respiratory disorders characterized by viscid or excessive mucus. It functions as a secretolytic and secretomotor agent, reducing mucus viscosity by stimulating the production of pulmonary surfactant by type II pneumocytes and enhancing ciliary activity in the respiratory tract. This dual action facilitates the clearance of phlegm and eases coughing. **Luorunchang** is a specific spray formulation of ambroxol hydrochloride developed by **Shandong Luoxin Pharmaceutical Group**, primarily indicated for pediatric use in acute respiratory tract infections. This formulation is designed to improve treatment compliance and provide a convenient alternative to traditional oral solutions, particularly in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ambroxol hydrochloride.